Cancer screening

Burning Rock Announces the Launch of China’s First Prospective Pan-Cancer Multi-omics Early Detection Study

Retrieved on: 
Wednesday, May 19, 2021

With support from the National Cancer Center, PRESCIENT is the first blood-based cancer screening and early detection study using a multi-omics approach in China.

Key Points: 
  • With support from the National Cancer Center, PRESCIENT is the first blood-based cancer screening and early detection study using a multi-omics approach in China.
  • Burning Rock\xe2\x80\x99s pan-cancer early detection technology has achieved strong initial results and I am very excited to work with Burning Rock and other clinical centers on this study.
  • Yusheng Han, Founder and CEO of Burning Rock, said, \xe2\x80\x9cPan-cancer early detection is one of Burning Rock\xe2\x80\x99s strategic priorities.
  • The launch of the PRESCIENT study after the PREDICT study demonstrates our unwavering commitment to early cancer detection.

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

Retrieved on: 
Wednesday, May 19, 2021

b'MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.

Key Points: 
  • b'MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.
  • "These final guidelines will encourage more clinicians to offer colorectal cancer screening to their patients starting at age 45.
  • Under these final guidelines, colorectal cancer screening remains a Grade A recommendation for people ages 50-75 and screening for ages 45 to 49 is a Grade B recommendation.
  • Cancer.

Introducing The Ezra Mammogram

Retrieved on: 
Tuesday, May 18, 2021

Ezra is addressing this problem by launching the fastest, easiest way to book a screening mammogram.\n"Unfortunately our current healthcare system is still often archaic even for the simplest of tasks: booking a screening exam.

Key Points: 
  • Ezra is addressing this problem by launching the fastest, easiest way to book a screening mammogram.\n"Unfortunately our current healthcare system is still often archaic even for the simplest of tasks: booking a screening exam.
  • With Ezra, booking a mammogram is now as easy as ordering an Uber: visit ezra.com, choose a facility, select a time for your mammogram, and done", said Mr. Emi Gal, co-founder & CEO of Ezra.\nEzra\'s mission is to detect cancer early for everyone.
  • The Company will be introducing the scan at its California locations in the upcoming weeks.\nWith the addition of the new plan, Ezra members now have the ability to choose between the following services:\nEzra has also recently introduced discounted multi-year plans.
  • The company\'s cancer screening services are available in New York, San Francisco, and Los Angeles.\nFor more information and to sign up for an Ezra membership, please visit ezra.com .\n'

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Retrieved on: 
Thursday, May 13, 2021

"\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Key Points: 
  • "\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.
  • "HPV self-sampling makes screening accessible to women who don\'t participate in screening or have limited access to screening.
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

New publication proves that Transpara by ScreenPoint Medical helps radiologists improve their accuracy with 3D mammography

Retrieved on: 
Wednesday, May 12, 2021

Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation: a multi-reader multi-case study.

Key Points: 
  • Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation: a multi-reader multi-case study.
  • This means customers who start using it for 2D mammography have a seamless transition to 3D without the costs of changing hardware.
  • "\nPieter Kroese, Chief Commercial Officer at ScreenPoint Medical said, "One of the main challenges of the transition from 2D to 3D mammography is the doubling of reading time.
  • This study shows that by using Transpara AI decision support, radiologists can not only read 3D mammograms more quickly, but they can also improve their accuracy.

Lung Association Turquoise Takeover Spreads Hope For Those Facing Lung Cancer During Pandemic

Retrieved on: 
Tuesday, May 11, 2021

The pandemic also temporarily delayed access to lung cancer screening for many people at high risk.

Key Points: 
  • The pandemic also temporarily delayed access to lung cancer screening for many people at high risk.
  • The American Lung Association\'s LUNG FORCE initiative\'s annual Turquoise Takeover celebration, from May 9 through May 15, unites America to raise critical awareness of lung cancer, the nation\'s #1 cancer killer.\nEvery year, LUNG FORCE celebrates Turquoise Takeover by turning landmarks and buildings across our nation turquoise - LUNG FORCE\'s signature color - to increase education and provide hope for those living with lung cancer.
  • Additionally, advancements in research have resulted in more than 30 new lung cancer treatments approved by the U.S. Food and Drug Administration (FDA) since 2016.\n"Despite encouraging improvements in the overall lung cancer survival rate, people of color who are diagnosed with lung cancer face worse outcomes compared to white Americans.
  • LUNG FORCE has three priorities: 1) Make lung cancer a cause that people care about and act on; 2) Educate and empower patients and healthcare providers and 3) Raise critical funds for groundbreaking lung cancer research.

Whiterabbit, Creator of AI to Improve and Streamline Breast Cancer Diagnoses, Emerges from Stealth to Announce New CEO and FDA Clearance

Retrieved on: 
Tuesday, May 11, 2021

This collaboration resulted in AI software that has been trained with decades-worth of breast cancer screening data.

Key Points: 
  • This collaboration resulted in AI software that has been trained with decades-worth of breast cancer screening data.
  • "\nWhiterabbit\'s executive team includes leading engineers, scientists, technologists, and world-class clinicians dedicated to advancing the process of breast cancer detection.
  • "\nWhiterabbit harnesses the power of data and artificial intelligence to improve the breast cancer screening process for radiologists and patients.
  • A growing number of radiologists and healthcare providers are using Whiterabbit\'s technology to improve patients\' experience with breast cancer screening.

Global Lung Cancer Diagnostic and Screening Test Market to Surpass US$ 3,515.9 Million by 2028, Says Coherent Market Insights (CMI)

Retrieved on: 
Thursday, May 6, 2021

b"According to Coherent Market Insights, the global lung cancer diagnostic and screening market is estimated to be valued at US$ 1,931.0 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2028).\nThe increasing number of screening test approvals from regulatory bodies is expected to drive growth of the lung cancer diagnostic and screening market during the forecast period.

Key Points: 
  • b"According to Coherent Market Insights, the global lung cancer diagnostic and screening market is estimated to be valued at US$ 1,931.0 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2028).\nThe increasing number of screening test approvals from regulatory bodies is expected to drive growth of the lung cancer diagnostic and screening market during the forecast period.
  • For instance, in June 2020, Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test.
  • The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations, who may be eligible for Enhertu, a HER2 directed antibody drug conjugate (ADC), which is currently in global phase 2 development for HER2 mutated or HER2 overexpressing NSCLC.\nThe increasing number of companion diagnostic approvals from regulatory bodies is expected to drive growth of the global lung cancer diagnostic and screening test market.
  • For instance, in August 2015 GE Healthcare announced to be the first company with a low dose computed tomography (CT) lung cancer screening option that is cleared by the U.S. FDA for lung cancer screening.\nKey players operating in the global lung cancer diagnostic and screening market include Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc ., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.\n"

Major independent study shows Transpara® AI by ScreenPoint Medical can reduce radiologists' workload up to 70% for both 2D and 3D mammography

Retrieved on: 
Thursday, May 6, 2021

The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.

Key Points: 
  • The authors also found that using Transpara AI to transition from 2D to 3D mammography (digital breast tomosynthesis) screening would yield a 30% reduction in workload, a 25% improvement in sensitivity and a 27% reduction in the screening recall rate.
  • Furthermore, many countries are challenged with the backlog of diagnosed cancer cases due to Covid-19 screening delays.
  • The higher the number the higher the risk, enabling radiologists to focus on those women facing the highest risk.
  • This saving is so important as there is a global shortage of radiologists, with workload also on the increase due to the introduction of new imaging techniques such as 3D breast tomosynthesis."

Oncologists Sound the Alarm on Drop in Cancer Screenings

Retrieved on: 
Wednesday, May 5, 2021

Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.

Key Points: 
  • Experts recommend regular screenings for breast cancer, prostate cancer, cervical cancer, colorectal cancer, and lung cancer.\nA study published last fall in the JCO Clinical Cancer Informatics found an 85 percent drop in breast cancer screenings and a 74 percent decline in prostate cancer screenings.
  • "These screenings could help detect cancer at its earliest, most treatable stage.
  • "\nDetecting cancer in the early stages, before it spreads, could make patients eligible for a non-surgical treatment option called proton therapy.\nProCure is New Jersey\'s most experienced proton therapy Center.
  • "That means fewer side effects and a lower risk of life-threatening medical issues.